Hepatitis B Therapeutics Landscape Discussed in In-demand GBI Research Study Published at MarketPublishers.com09 Oct 2015 • by Natalie Aster
LONDON – In spite of being considered as a vaccine-preventable disease, hepatitis B remains a serious health threat worldwide. The incidence of the disease is higher in countries with a huge number of migrants from medium-to-high prevalence nations. Around 350 million people globally are infected with chronic hepatitis B, which causes considerable morbidity and mortality. Close to 780,000 patients die from hepatitis B every year, of which 650,000 deaths are owing to complications like liver cancer and cirrhosis. In spite of this, rates of diagnosis and treatment are poor, arising from its asymptomatic nature.
The global hepatitis B therapeutics market is served comparatively well by the currently available products, of which Viread and Baraclude are the most-prescribed prescribed ones. However, both medications have received black-box warnings from the FDA, indicating that the market experiences a high level of unmet need.
By 2021, the hepatitis B market in the 8 leading markets is poised to grow from a value of USD 2.9 billion to USD 3.5 billion, posting a 2.3% CAGR.
In-demand report “Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth” elaborated by GBI Research presents an in-depth overview of the hepatitis B market, examining symptoms, etiology, epidemiology, pathophysiology, diagnosis, and treatment options. It identifies the therapeutic strategies for the treatment of the disease, products, and firms dominating the present-day marketed products landscape and recognise gaps and unmet clinical needs. It sheds light on key pipeline trends by ROA, molecule type, mechanism of action, MOA and novelty. The report examines key market opportunities and possible risks by examining trends in clinical study size, duration, and failure rate by development stage, molecule type, and MOA. It reviews the molecules in late stage development that have shown strong therapeutic potential by canvassing clinical study data and multi-scenario product forecasts. Comparisons of usage patterns for hepatitis B treatment, annual treatment costs, and market growth prospects are provided. The report also examines major trends in co-development and licensing deals relating to hepatitis B products, alongside identifying the key strategic consolidations which have shaped the commercial landscape.
Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth
Published: September, 2014
Price: US$ 4,995.00
More studies by the publisher can be found at GBI Research page.